Dr. Mel Spigelman, CEO of TB Alliance, said: “These partnerships show that the TB Alliance is aggressively increasing the depth and strength of its portfolio to ensure that promising new TB drug candidates continue moving toward the clinic.
“Tuberculosis is responsible for the death of one person approximately every 20 seconds and there is a significant need for novel medications to combat growing bacterial resistance to current drugs and to reduce the duration and complexity of therapy,” he added.